MedWatch

New Danish company found its main asset and initiates clinical trials in 2020

Danish Antag Therapeutics has chosen its main asset and is now preparing for pre-clinical and later clinical trials. At the same time, one more experienced biotech offier enters the board of directors.

Foto: Giulia Mangione

Things are looking up for the young Danish company Antag Therapeutics that was founded in February last year and four months later received a DKK 20 million (USD 3.08 million) investment from Novo Seeds.

Now, the company has identified the most promising candidates, and the way is paved for pre-clinical trials and later on, clinical studies.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier